{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:59:48Z","timestamp":1781243988550,"version":"3.54.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Inflammatory myofibroblastic tumor (IMT) is an extremely rare mesenchymal tumor with approximately 50% of cases harbor anaplastic lymphoma kinase (ALK) gene rearrangements. The tyrosine kinase inhibitor (TKI) treatment has been increasingly common for IMTs with ALK fusions, but evidence for the efficacy of TKIs in uterine IMT is lacking. In this report, we present a case of patient with recurrent uterine IMT harboring\n                    <jats:italic>IGFBP5-ALK<\/jats:italic>\n                    fusion. The patient was initially misdiagnosed as uterine myxoid leiomyoma and then leiomyosarcoma after recurring. Then the patient was recommended ALK-TKIs treatment after detecting ALK rearrangement, and achieved complete response (CR) from a second-generation ALK-TKI inhibitor, iruplinalkib, after resistance to the first-generation inhibitor crizotinib. This is the first case of iruplinalkib achieved therapeutic success in uterine IMT, suggesting that a sequential ALK-TKIs with iruplinalkib could be an optimal targeted therapeutic strategy for ALK-rearranged IMTs.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1851744","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:45:29Z","timestamp":1781243129000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboring IGFBP5-ALK fusion with sustained response to iruplinalkib"],"prefix":"10.3389","volume":"16","author":[{"given":"Ke","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runfeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","volume-title":"Soft tissue and bone tumours","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0575-ra","article-title":"Inflammatory myofibroblastic tumor in female genital tract","volume":"143","author":"Shukla","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2022.02.008","article-title":"Update on uterine mesenchymal neoplasms","volume":"15","author":"Kertowidjojo","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1461092","article-title":"Uterine inflammatory myofibroblastic tumor: a retrospective analysis","volume":"14","author":"Bai","year":"2024","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154335","article-title":"Uterine inflammatory myofibroblastic tumor","volume":"242","author":"Karpathiou","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.69","article-title":"Inflammatory myofibroblastic tumor of the uterus: A clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum","volume":"30","author":"Bennett","year":"2017","journal-title":"Mod Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001120","article-title":"ALK is a specific diagnostic marker for inflammatory myofibroblastic tumor of the uterus","volume":"42","author":"Mohammad","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100852","article-title":"Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy","volume":"37","author":"Kyi","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1147974","article-title":"Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhaue","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100143","article-title":"Leiomyoma-like morphology in metastatic uterine inflammatory myofibroblastic tumors","volume":"36","author":"Devins","year":"2023","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-005142","article-title":"Uterine inflammatory myofibroblastic tumor with myxoid predominance: diagnostic challenge","volume":"34","author":"Rodrigues","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001904","article-title":"Histopathologic and molecular characterization of uterine leiomyoma-like inflammatory myofibroblastic tumor comparison to molecular subtypes of uterine leiomyoma","volume":"46","author":"Kuisma","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/PAS.0000000000000593","article-title":"Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms","volume":"40","author":"Parra-Herran","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000801","article-title":"Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1","volume":"41","author":"Haimes","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: from function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2021.07.016","article-title":"Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE","volume":"156","author":"Sch\u00f6ffski","year":"2021","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241298489","article-title":"Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib-a case report","volume":"16","author":"Becht","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01144-6","article-title":"Update of diagnosis and targeted therapy for ALK+ Inflammation myofibroblastic tumor","volume":"24","author":"Wang","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01970-w","article-title":"Iruplinalkib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1720854","article-title":"Case Report: IGFBP5- ALK fusion-positive case of high-grade endometrial stromal sarcoma with response to ALK-targeted therapy","volume":"15","author":"Zhang","year":"2026","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1851744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:45:32Z","timestamp":1781243132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1851744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1851744"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1851744","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1851744"}}